Bank of America
GRCE

Bank of America’s Grace Therapeutics GRCE Stock Holding History

Bank of America’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Sell
494,698
-25
-0% -$69 ﹤0.01% 4557
2026
Q1 		$2.29M Buy
494,723
+25
+0% +$98 ﹤0.01% 4030
2025
Q4 		$1.71M Hold
494,698
– – ﹤0.01% 4190
2025
Q3 		$1.47M Hold
494,698
– – ﹤0.01% 5069
2025
Q2 		$1.47M Hold
494,698
– – ﹤0.01% 5016
2025
Q1 		$1.13M Hold
494,698
– – ﹤0.01% 5139
2024
Q4 		$1.85M Hold
494,698
– – ﹤0.01% 4512
2024
Q3 		$1.48M Hold
494,698
– – ﹤0.01% 4783
2024
Q2 		$1.44M Hold
494,698
– – ﹤0.01% 4666
2024
Q1 		$1.69M Hold
494,698
– – ﹤0.01% 4553
2023
Q4 		$1.43M Hold
494,698
– – ﹤0.01% 4703
2023
Q3 		$1.38M Buy
+494,698
New +$1.17M ﹤0.01% 4577
2022
Q2 		– Sell
-9,431
Closed -$69K – 8468
2022
Q1 		$69K Buy
9,431
+5,994
+174% +$42.7K ﹤0.01% 7032
2021
Q4 		$26K Buy
3,437
+3,333
+3,205% +$30.1K ﹤0.01% 7443
2021
Q3 		$1K Buy
104
+52
+100% +$1.02K ﹤0.01% 8025
2021
Q2 		$1K Hold
52
– – ﹤0.01% 7659
2021
Q1 		$2K Hold
52
– – ﹤0.01% 7263
2020
Q4 		$1K Sell
52
-42
-45% -$485 ﹤0.01% 7025
2020
Q3 		$1K Hold
94
– – ﹤0.01% 6799
2020
Q2 		$2K Hold
94
– – ﹤0.01% 6689
2020
Q1 		$2K Sell
94
-1,600
-94% -$56.7K ﹤0.01% 6660
2019
Q4 		$199K Buy
1,694
+1,608
+1,870% +$159K ﹤0.01% 5642
2019
Q3 		$8K Buy
+86
New +$7.96K ﹤0.01% 6767
2019
Q1 		– Sell
-787
Closed -$31K – 7468
2018
Q4 		$31K Buy
+787
New +$34.3K ﹤0.01% 6372
2014
Q1 		– Sell
-1
Closed – – 8125
2013
Q4 		$0 Buy
+1
New +$819 ﹤0.01% 8182

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Bank of America's GRCE Position: Q2 2026 in Review

Bank of America reduced its Grace Therapeutics (GRCE) stake by 0.01% in Q2 2026, selling an estimated $69 and leaving 494,698 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #4557.

Bank of America first reported a position in GRCE in Q4 2013 and has held it in 25 quarters since. The position peaked at $2.29M in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Bank of America held 494,698 shares of Grace Therapeutics worth $1.12M as of Q2 2026.
  • Bank of America sold 25 Grace Therapeutics shares in Q2 2026, an estimated $69.
  • Grace Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #4557 holding.
  • Bank of America first reported a position in Grace Therapeutics in Q4 2013 and has held it in 25 quarters since.
  • Bank of America's Grace Therapeutics position peaked at $2.29M in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.